Nazione: Cipro
Lingua: greco
Fonte: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
TOPOTECAN HYDROCHLORIDE
VENUS PHARMA GMBH (0000008606) AM BAHNHOF 1-3, WERNE, 59368
L01CE01
TOPOTECAN
4MG/VIAL
ΚΟΝΙΣ ΓΙΑ ΕΝΑΙΩΡΗΜΑ ΠΡΟΣ ΕΓΧΥΣΗ
TOPOTECAN HYDROCHLORIDE (8000001521) 4,34MG
INTRAVENOUS USE
Εθνική Διαδικασία
TOPOTECAN
Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 5 VIALS X 4MG (310033601) 5 VIAL - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται
Page 2 of 15 1 . NAME OF THE MEDICINAL PRODUCT Topotecan Venus 4mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 4 mg topotecan (as hydrochloride). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. Light yellow to greenish powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Topotecan Venus monotherapy is indicated for the treatment of: patients with metastatic carcinoma of the ovary after failure of first-line or subsequent t h e r a py. patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the f i rs t - line regimen is not considered appropriate (see section 5.1). Topotecan Venus in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy and should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section 6.6). When used in combination with cisplatin, the full prescribing information for cisplatin should be consulted. Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of ≥ 1.5 x 10 9 /l, a platelet count of ≥ 100 x 10 9 /l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary). Page 3 of 15 Topotecan Venus must be reconstituted and further diluted before use (see section 6.6). _Ovarian and Small Cell Lung Carcinoma_ _Initial dose_ The recommended dose of topotecan is 1.5 mg/m 2 body surface area/day administered by intravenous infusion over 30 minutes daily for 5 consecutive days with a 3 week interval between the start of ea Leggi il documento completo